The global market for Contract Research and Manufacturing Services (CRAMS) is estimated at US$128.8 Billion in 2023 and is projected to reach US$211.4 Billion by 2030, growing at a CAGR of 7.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the CRAMS market is driven by several factors, including the increasing complexity of pharmaceutical production, heightened cost pressures faced by drug developers, and a surge in the number of small to mid-size biotech companies. Technological advancements in drug development processes have necessitated the adoption of highly specialized manufacturing capabilities that many pharmaceutical companies do not have in-house. This has increased their reliance on CRAMS providers who possess the necessary technological infrastructure and expertise.
Additionally, the rising focus on cost-efficiency within the pharmaceutical industry has propelled companies to seek external partners that can provide economies of scale and scope in both research and production phases. Consumer behavior has also influenced the CRAMS market, particularly as there is an increasing demand for faster development and delivery of new therapies to the market, which CRAMS can facilitate. Moreover, the growth of the biologics sector, which requires distinct production environments and expertise, continues to drive the expansion of CRAMS, making it an essential component of the modern pharmaceutical supply chain.
The growth in the CRAMS market is driven by several factors, including the increasing complexity of pharmaceutical production, heightened cost pressures faced by drug developers, and a surge in the number of small to mid-size biotech companies. Technological advancements in drug development processes have necessitated the adoption of highly specialized manufacturing capabilities that many pharmaceutical companies do not have in-house. This has increased their reliance on CRAMS providers who possess the necessary technological infrastructure and expertise.
Additionally, the rising focus on cost-efficiency within the pharmaceutical industry has propelled companies to seek external partners that can provide economies of scale and scope in both research and production phases. Consumer behavior has also influenced the CRAMS market, particularly as there is an increasing demand for faster development and delivery of new therapies to the market, which CRAMS can facilitate. Moreover, the growth of the biologics sector, which requires distinct production environments and expertise, continues to drive the expansion of CRAMS, making it an essential component of the modern pharmaceutical supply chain.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Manufacturing Service segment, which is expected to reach US$126.8 Billion by 2030 with a CAGR of a 6.8%. The Research Service segment is also set to grow at 8.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $35.1 Billion in 2023, and China, forecasted to grow at an impressive 11.5% CAGR to reach $46.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Contract Research and Manufacturing Services (CRAMS) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Contract Research and Manufacturing Services (CRAMS) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Contract Research and Manufacturing Services (CRAMS) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie Inc., Arch Pharmalabs Ltd., Calyx Chemicals and Pharmaceuticals Ltd., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 86 Featured):
- AbbVie Inc.
- Arch Pharmalabs Ltd.
- Calyx Chemicals and Pharmaceuticals Ltd.
- Globela Pharma Pvt. Ltd.
- Ind-Swift Laboratories Ltd.
- Merck KGaA,
- MSN Laboratories
- Murli Krishna Pharma Private Ltd.
- Novartis AG
- Orchid Pharma Ltd.
- SMS Pharmaceuticals Ltd.
- Sun Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific Inc.
- Ultratech India Limited
- VIVAN Life Sciences Pvt Ltd.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned
- AbbVie Inc.
- Arch Pharmalabs Ltd.
- Calyx Chemicals and Pharmaceuticals Ltd.
- Globela Pharma Pvt. Ltd.
- Ind-Swift Laboratories Ltd.
- Merck KGaA,
- MSN Laboratories
- Murli Krishna Pharma Private Ltd.
- Novartis AG
- Orchid Pharma Ltd.
- SMS Pharmaceuticals Ltd.
- Sun Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific Inc.
- Ultratech India Limited
- VIVAN Life Sciences Pvt Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | November 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 128.8 Billion |
| Forecasted Market Value ( USD | $ 211.4 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
